Table 3. Clinical outcome Patient no. .... | American Society of Hematology

Table 3.

Clinical outcome

Patient no.	Status at study entry	Time and site of PD	Site of grades II-IV acute GVHD	Site of chronic GVHD	No. of DLIs	Overall best response	Outcome
BCC group
1	PR	—†	—	—	—	CR	Died in PD, d 245
2	SD	—	—	Eye, mouth	—	CR	Alive in CR, d 1119
3	PR	d 43; skin	Skin, GI	GI	—	SD	Died in PD, d 239
4	SD	d 310; bone, liver	—	Skin, GI	—	SD	Died in PD, d 537
5	SD	d 84; bone	GI	GI	—	SD	Alive in SD, d 633
6	SD	d 59; bone	—	—	3	MR	Alive in SD. d 646
7	SD	d 166; bone	—	Mouth	2	SD	Died in PD, d 404
8	PR	—	—	Eye, mouth, liver	—	SD	Alive in SD, d 345
RCC group
9	PD	d 160; liver	Skin, GI	Skin, eye	—	CR	Alive in CR, d 1015
10	PD	—	Skin, GI	—	—	SD	Died in SD, d 76 (acute ML)
11^*	PD	d 370; lung	GI	Skin, mouth	—	PR/CR‡	Died in CR, d 590 (TTP)
12	PD	d 27; renal fossa	—	—	—	SD	Died in SD, d 85 (ARDS)
13	PD	d 94; lymph nodes	—	—	1	PD	Died in PD, d 245
14	PD	d 32; renal fossa	GI	—	—	MR	Died in SD, d 175 (pneumonia)
15	PD	d 153; abdominal mass	—	—	2	MR	Died in PD, d 374
16	PD	d 50; renal fossa	—	—	1	PD	Died in PD, d 221
17	PD	d 78; bone, lung	—	Skin	—	PD	Died in PD, d 262
18	PD	—	Skin (IV)	—	—	ED	Died, d 19 (GVHD)
19	PD	d 176; lung, soft tissue mass	—	Skin	—	MR	Alive in SD, d 405
20	PD	d 28; bone	—	—	4	MR	Alive in PD, d 319
21^*	PD	d 29; lung, liver	Liver	—	—	SD	Died in PD d 123
22	SD	—	—	—	—	PR	Alive in PR, d 229
23	PR	—	Liver	—	—	CR§	Alive in CR, d 97

Patient no.	Status at study entry	Time and site of PD	Site of grades II-IV acute GVHD	Site of chronic GVHD	No. of DLIs	Overall best response	Outcome
BCC group
1	PR	—†	—	—	—	CR	Died in PD, d 245
2	SD	—	—	Eye, mouth	—	CR	Alive in CR, d 1119
3	PR	d 43; skin	Skin, GI	GI	—	SD	Died in PD, d 239
4	SD	d 310; bone, liver	—	Skin, GI	—	SD	Died in PD, d 537
5	SD	d 84; bone	GI	GI	—	SD	Alive in SD, d 633
6	SD	d 59; bone	—	—	3	MR	Alive in SD. d 646
7	SD	d 166; bone	—	Mouth	2	SD	Died in PD, d 404
8	PR	—	—	Eye, mouth, liver	—	SD	Alive in SD, d 345
RCC group
9	PD	d 160; liver	Skin, GI	Skin, eye	—	CR	Alive in CR, d 1015
10	PD	—	Skin, GI	—	—	SD	Died in SD, d 76 (acute ML)
11^*	PD	d 370; lung	GI	Skin, mouth	—	PR/CR‡	Died in CR, d 590 (TTP)
12	PD	d 27; renal fossa	—	—	—	SD	Died in SD, d 85 (ARDS)
13	PD	d 94; lymph nodes	—	—	1	PD	Died in PD, d 245
14	PD	d 32; renal fossa	GI	—	—	MR	Died in SD, d 175 (pneumonia)
15	PD	d 153; abdominal mass	—	—	2	MR	Died in PD, d 374
16	PD	d 50; renal fossa	—	—	1	PD	Died in PD, d 221
17	PD	d 78; bone, lung	—	Skin	—	PD	Died in PD, d 262
18	PD	—	Skin (IV)	—	—	ED	Died, d 19 (GVHD)
19	PD	d 176; lung, soft tissue mass	—	Skin	—	MR	Alive in SD, d 405
20	PD	d 28; bone	—	—	4	MR	Alive in PD, d 319
21^*	PD	d 29; lung, liver	Liver	—	—	SD	Died in PD d 123
22	SD	—	—	—	—	PR	Alive in PR, d 229
23	PR	—	Liver	—	—	CR§	Alive in CR, d 97

— indicates not applicale; GI, gastrointestinal; MI, myocardial infarction; ARDS, acute respiratory distress syndrome; and ED, early death.

Patient received bone marrow from a matched but unrelated donor.

Patient lost follow-up after day 95.

Patient underwent metastasectomy and became surgical CR.

Patient underwent RTX to site of evaluable disease before transplantation and is not included as CR in analysis.